Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Cytosorbents (CTSO) over the last 7 years, with Q3 2025 value amounting to $2.1 million.

  • Cytosorbents' Non-cash Items fell 4067.8% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 4067.8%. This contributed to the annual value of $3.0 million for FY2024, which is 3765.41% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Non-cash Items is $2.1 million, which was down 4067.8% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Non-cash Items ranged from a high of $8.0 million in Q3 2023 and a low of $2.1 million during Q3 2025
  • In the last 5 years, Cytosorbents' Non-cash Items had a median value of $4.4 million in 2024 and averaged $4.5 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first skyrocketed by 6060.61% in 2021, then plummeted by 5569.46% in 2024.
  • Quarter analysis of 5 years shows Cytosorbents' Non-cash Items stood at $5.9 million in 2021, then decreased by 20.01% to $4.7 million in 2022, then rose by 2.59% to $4.9 million in 2023, then plummeted by 37.65% to $3.0 million in 2024, then tumbled by 30.81% to $2.1 million in 2025.
  • Its Non-cash Items was $2.1 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.3 million in Q1 2025.